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 "We are not tinkers who merely patch and mend what is broken... we must be watchmen, guardians 
of the life and the health of our generation, so that stronger and more able generations may come 
after. "Dr Elizabeth Blackwell (1821-1910), the first woman doctor 
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Introduction 
The UK’s Health System is in crisis, central funding no longer keeping pace with demand. Traditional 
responses- spending more, seeking efficiency savings or invoking market forces- are not solutions. The 
health of our nation demands urgent delivery of a radical new model, negotiated openly between 
public, policymakers and healthcare professionals. Without such action, the prognosis for our 
healthcare system- and for the health of the individuals it serves- may be grim. Here, we explore such 
a new prescription for our national health. 
 
A perfect storm for the NHS  
Historically, real-term UK National Health Service (NHS) expenditure has risen by 3.7%/year. From 
2009/10- 2020/21, this will fall to <1%/year- half the previous lowest decadal average1. Population 
growth will limit per capita growth to 0.1%/year. However, costs are rising faster- with 
drug/technology innovation, and as patient expectations, the prevalence of non-communicable 
diseases, the number of elderly patients and the impacts of chronic disability rise2: the number of 
people with multiple long-term conditions is projected to grow from 1.9 million in 2008 to 2.9 million 
in 20183.  
The Department of Health’s small total budget underspend (1.5% in 2012/13 and only 0.001% in 
2014/15) became an overspend of £149m in 2015/16 (defined using the Total Department 
Expenditure Limit excluding depreciation (TDEL))(Figure 1). Likewise, 11% of NHS healthcare providers 
were in deficit in 2012/13, rising to 65% in 2015/16. Impacts are most severe amongst acute trusts, 
with 85% reporting a deficit by December 2015 (Figure 2). Key performance metrics have worsened. 
Poor health/social care integration means that many hospital beds are blocked by those not needing 
hospitalization. 
Past responses have failed. ‘Improving efficiency’ is insufficient4, the benefits of ‘competition’ 
unclear5, ‘local solutions’ often inefficient and poorly evaluated. And these do not address the root 
causes of the challenges facing the NHS. The approach society takes to maintaining health requires 
fundamental reappraisal.  
 
The Costs of Focusing on Disease Treatment 
The NHS is primarily a ‘disease detection and treatment’ service- such activity being heavily 
incentivised. Primary and secondary care are poorly integrated, and inappropriately structured to deal 
with the social care crisis. The result is the overburdening of acute care with (sometimes minor) 
preventable conditions, a disproportionate expenditure on treating end-stage disease (often with 
limited impact) and inadequate support for compassionate end-of-life care. Even in 2001, 25% of US 
healthcare costs were accrued in the last year of life6. In the UK, by far the largest cost element of end-
of-life care relates to hospital care- averaging £4,500 per person during the final 90 days of life7. Over 
a third of patients receive non-beneficial hospital treatments in their last six months of life: the pooled 
prevalence of non-beneficial chemotherapy is 33% and, for Intensive Care Unit (ICU) admission, 10%8. 
Such ‘intensive healthcare’ risks many - especially the elderly with multiple chronic morbidities- 
becoming ‘hospital-dependent’, with progressive functional decline to death’9,10. By 2004, one in five 
Americans who died already did so on, or shortly after admission to, an ICU11. Around two-thirds of 
people would prefer to die at home, yet only one in five do- the bulk of the rest dying in hospital12 13. 
 
Use of adult ICU beds (in particular by the elderly, many with complex co-morbidities) is rising steeply, 
costing £1.6bn in 2012-13 in England alone. Over 1/5th of those admitted will not survive hospital 
admission. The majority of the sickest who do, will suffer significant impacts on mental health and 
physical function which persist long after hospital discharge14. At the other end of the age spectrum, 
Neonatal Intensive Care can be lengthy (134 days and 116 days after birth at 23 and 24 weeks 
gestation, respectively), with ½ and 1/3 respectively not surviving15. Only 53% born at 23 weeks 
gestation (and 65% at 24 weeks) survive free of any impairment at 3 years16, and 29% and 19% 
respectively suffer severe disability. Thus, although affecting only a small minority of births, care for 
extremely low gestational age births consumes a high proportion of resources, and brings with it a 
substantial physical, emotional and fiscal cost including that relate to social care and education: at 23 
weeks, incremental public sector costs per survivor over childhood are £234,497 for those born at 23 
weeks and £169,928 at 24 weeks17. For older children, increasing admissions to UK paediatric ICUs are 
in part due to the increasing numbers of children living with long term life limiting conditions18. Some 
who would have previously been allowed to die are now kept alive to survive with significant 
disability19. Decisions to withdraw care are increasingly contested, and taking such cases to court is 
time consuming and costly. Average PICU length of stay is rising, largely as a consequence of 
protracted care for patients who ultimately die20. Whilst successful outcomes should be celebrated, 
this approach is also creating a technology-dependent subpopulation with a high mortality rate and, 
for survivors, high readmission rate and, often, a questionable quality of life21,22. Resources spent in 
this way are not available to prevent sickness, or to offer social or medical support to others. 
Meanwhile, cancer treatment cost the European Union some €126 billion in 200923. Survival gains 
attributed to new anti-cancer therapies often used in the advanced/metastatic settings have 
remained modest for many solid tumours: of 71 anticancer therapies approved by the FDA between 
2002-2014, the median overall survival incremental improvement was 2.1 months24. Meanwhile, new 
cancer therapies cost nearly $10,000/month, prompting discussions concerning the disconnect 
between cost and efficacy25. 
 
The Wrong Model? 
Our current system is focused not on ‘Health Maintenance’ but ‘Treatment of Disease’- much of it 
driven by factors (environmental, social deprivation, unhealthy consumption patterns/lifestyles) not 
generally regulated and managed through the ‘health’ system.  
Many cancers are caused by lifestyle factors (e.g. tobacco and alcohol use, unhealthy diets and 
sedentary behaviour) exacerbated by poor policy choices e.g. relating to taxation, urban design and 
transport. Nearly 42% of UK cancers would simply not occur were such environmental/lifestyle factors 
addressed26. These lifestyle interventions (exercise, improved diet, reduced smoking/alcohol 
consumption) also reduce the burden of other prevalent diseases (such as diabetes, obesity and 
cardiovascular disease): 80% of premature cardiovascular disease cases may be preventable27. Primary 
prevention can be highly cost effective: in 2002, Derek Wanless reported that compared with ‘slow 
uptake’ a ‘fully engaged scenario’ of action to protect and promote health would save £30bn in total 
NHS spendingannually28. However, in 2015, two thirds of UK adults were obese or overweight, half of 
adult women got insufficient exercise, a third of adults drank too much alcohol, and a fifth still 
smoked29. 
Although some unhealthy products are taxed, the scale inadequately discourages their use (e.g. 
tobacco and alcohol). Other large external costs (‘externalities’) are not covered by existing taxes, 
including the costs of ill health due to other dietary factors, air pollution or physical inactivity. Thus, 
many industries do not pay for the health impacts associated with the use of their products which are 
thus effectively subsidised by the public purse. Such subsidies for fossil fuels, related to air pollution, 
amounted to about $20.56bn in 2015 in the UK30.  
 
Potential Solutions 
The scope for increased efficiency (‘doing the same for less’) is both limited and insufficient. Just 
spending more’ cannot be an answer. Nor is increased commercial competition in a “healthcare 
market”: US healthcare - the world’s most market-based and expensive (18% of GDP)- delivers life 
expectancy is at the lower end of OECD economies, with poorly-controlled cost inflation.  
The House of Lords Committee on the long term sustainability of the NHS31 provides an opportunity 
to look critically at potential alternative solutions to the growing crisis. A number are worthy of 
consideration.  
Firstly, we must rapidly move to a focus on disease prevention without undue medicalization. This 
must be driven by focusing on healthier environments and taxing externalities, and through changes 
in public policy in fields traditionally considered divorced from health (such as transport, advertising, 
fuel and food taxation) as well as smoking/alcohol consumption. Such action should be supplemented 
by concerted engagement to drive changes in behaviour. Meanwhile, cost effective management of 
multi-morbidity requires much more engagement of patients and carers, investment in self-
management, and evidence based decision support32.  
Much ill-health relates to social inequality, for which all must pay. Addressing social inequities needs 
re-affirmation as a central pillar of health policy33. 
 
An informed conversation must be developed between healthcare professionals, politicians, and the 
public about the true costs and effectiveness of some aspects of medical care. What activity is really 
beneficial or cost-effective and to what degree? The issue of ‘opportunity cost’ when financial 
resources are limited must be recognised and addressed, without fear of discussion of ‘rationing’. 
Could diverting monies to preventative measures and to reducing social inequalities offer ‘the greatest 
gain to the greatest number’? What should and should not (or perhaps, could and could not) be 
provided, and why? The issue, then, relates less to a generic ‘when not to treat the sick’ than to the 
specifics of when such intervention prolongs suffering for limited gain or carries sufficient cost as to 
deprive others the effective care they might seek.  
The central role of NICE in prioritizing cost effective technologies, interventions and policies must be 
reinforced with a particular emphasis on public health interventions and the relative costs of 
prevention and treatment. 
Primary care must be bolstered. It provides the opportunity for targeted prevention, as well as for the 
coordinated care of patients with multi-morbidity, including end of life care. Closer integration with 
secondary care could facilitate the management of complex disease and social challenges.  
The disproportionate and often inappropriate expenditure on the management of end stage disease, 
often in hospital settings (rather than at home or in a hospice), stems partly from failure to provide 
universal access to effective end of life care and to foster public discourse about the limits to 
technological salvage of advanced disease. Effective palliative care results in improved mood, quality 
of life and perhaps survival than standard care34,35 which is all too often based on the mistaken 
assumption that more intervention results in better outcomes. 
An urgent priority is to act on the recommendations of the Dilnot report which proposed modest 
increases in social care funding and could significantly reduce pressures on acute beds from elderly 
patients requiring social care36.  
A coherent policy for sustaining and promoting health must be created, and in a way that removes the 
NHS from its role as a party political football, subject to ideologically motivated ‘reforms ‘ and with 
the instigation of targets driven by political rather than health economic endpoints, often with 
debilitating effects. Establishing health policy should be further distanced from direct control by 
Government - thus promoting evidence-based rather than ideologically-driven decision-making. 
Meanwhile, governance could be greatly improved by setting up an independent standing Commission 
with the technical capacity to hold Governments to account for providing humane, cost effective care 
and prevention whilst engaging the public in much needed discussions about the limits to curative 
medicine and the causes of disease.   
Such action is urgent. It cannot be delayed. To do so risks the health of our nation, the sustainability 
of the NHS, and the vitality of our nation state. 
 
Contributors and Sources 
This article arose from discussions held at St. George’s House, Windsor, UK in November 2015. We 
thank all participants for the useful discussion. Participants contributed to the themes of this article, 
but cannot be held responsible for any errors of commission, omission or emphasis in this text. 
As their job titles attest, all authors are senior in their fields and have extensive relevant clinical and 
academic experience. Each provided text relevant to their expertise, which was collated by HM, who 
acts as guarantor of the article.  All authors contributed to editing and shaping the final article. 
 
Key Messages 
 Current models of UK heath care provision are unsustainable 
 Incremental modifications of past solutions (‘efficiency savings’ or ‘internal market 
modification’ are not the answer: radical process re-engineering focussed on patient, not 
disease, and cause, rather than cure, is required. 
 Policies which support health, rather than address treating disease, must be prioritised- 
recognising that much of such policy lies in domains (such as transport, urban planning, food 
and energy policy) that lie outside conventional ‘health systems’ 
 A mature and open conversation between health professionals, politicians and public is 
required, relating to the true costs and effectiveness of some strands of medical care: to what 
should and should not (or perhaps, could and could not) be provided: and to the issue of 
‘opportunity cost’. The limits of the medical approach to progressive/terminal diseases should 
be acknowledged and the focus shifted from relentless (often ineffective) treatment to 
delivering care that maximises quality of life. 
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